Literature DB >> 27790502

Rifampicin-Induced Concomitant Renal Injury and Hepatitis.

Bharti Chogtu1, Vyshak Uddur Surendra2, Rahul Magazine3, Preetam Rajgopal Acharya4, Devesh Bhaskar Yerrapragada5.   

Abstract

Adverse drug reactions are not unusual during Anti-Tubercular Therapy (ATT). One of the common complications of anti-tubercular treatment is drug induced hepatitis and renal insufficiency has also been reported. Renal failure and/or hepatitis encountered during treatment of tuberculosis can have varied aetiologies: drug induced, concomitant viral infection, pre-existing co-morbidities or a combination of these. Since, hepatitis and/or renal insufficiency can be life threatening a prompt diagnosis is warranted, where drugs should be kept as one of the important cause. Identifying the drug helps in treating hepatitis and/or renal insufficiency along with helping the physician to change the combination of ATT regimen. Rifampicin is one of the most important first line drugs in the treatment of tuberculosis. Hepatitis, epigastric distress, anaemia, thrombocytopenia, and interstitial nephritis are reported adverse drug reactions to rifampicin. As per literature rifampicin induced renal toxicity is usually seen on rifampicin re-exposure, or rifampicin administration on alternate days, both being present in this case. Here we are reporting a case of ATT induced renal failure with concomitant hepatitis where rifampicin was suspected to be the cause.

Entities:  

Keywords:  Anti tubercular drugs; Liver function tests; Serum creatinine; Serum urea

Year:  2016        PMID: 27790502      PMCID: PMC5072002          DOI: 10.7860/JCDR/2016/21030.8578

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

Review 1.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

2.  Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.

Authors:  Ramesh Kumar; Vikram Bhatia; Shankar Khanal; V Sreenivas; S Datta Gupta; Subrat K Panda; Subrat K Acharya
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

3.  Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.

Authors:  Rohit Singla; Surendra K Sharma; Alladi Mohan; Govind Makharia; V Sreenivas; Brajesh Jha; Sanjeev Kumar; Pawan Sarda; Sarman Singh
Journal:  Indian J Med Res       Date:  2010-07       Impact factor: 2.375

4.  Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara.

Authors:  Anupa Khadka Chhetri; Anupa Khatri Chhetri; Archana Saha; Sharat Chandra Verma; Subish Palaian; Pranaya Mishra; Pathiyil Ravi Shankar
Journal:  J Pak Med Assoc       Date:  2008-10       Impact factor: 0.781

5.  Capreomycin-induced optic neuritis in a case of multidrug resistant pulmonary tuberculosis.

Authors:  Rahul Magazine; Mahuya Pal; Bharti Chogtu; Veena Nayak
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

6.  A clinical description of rifampicin-induced acute renal failure in 170 consecutive cases.

Authors:  A Covic; O Golea; L Segall; Srinath Meadipudi; Liliana Munteanu; M Nicolicioiu; V Tudorache; Maria Covic; D J A Goldsmith
Journal:  J Indian Med Assoc       Date:  2004-01

Review 7.  Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: a case report and literature review.

Authors:  Sahoko Chiba; Kimitake Tsuchiya; Hiroyuki Sakashita; Eisaku Ito; Naohiko Inase
Journal:  Intern Med       Date:  2013       Impact factor: 1.271

8.  Acute renal failure due to rifampicin: a study of 25 patients.

Authors:  Thangamani Muthukumar; Matcha Jayakumar; Edwin M Fernando; Muthayeepalayam A Muthusethupathi
Journal:  Am J Kidney Dis       Date:  2002-10       Impact factor: 8.860

Review 9.  Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.

Authors:  W Barcellini; B Fattizzo
Journal:  Dis Markers       Date:  2015-12-27       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.